Kenneth Hoberman is Director of TG THERAPEUTICS, INC.. Currently has a direct ownership of 264,935 shares of TGTX, which is worth approximately $4.85 Million. The most recent transaction as insider was on Jun 19, 2024, when has been sold 22,250 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 265K
9.17% 3M change
18.97% 12M change
Total Value Held $4.85 Million

Kenneth Hoberman Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 19 2024
BUY
Grant, award, or other acquisition
-
22,250 Added 7.75%
264,935 Common Stock
Sep 28 2023
BUY
Grant, award, or other acquisition
-
20,000 Added 7.61%
242,685 Common Stock
Jul 20 2022
BUY
Grant, award, or other acquisition
-
43,732 Added 16.41%
222,685 Common Stock
Jun 18 2021
BUY
Grant, award, or other acquisition
-
20,000 Added 10.05%
178,953 Common Stock

Also insider at

NVCT
Nuvectis Pharma, Inc. Healthcare
KH

Kenneth Hoberman

Director
New York, NY

Track Institutional and Insider Activities on TGTX

Follow TG THERAPEUTICS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TGTX shares.

Notify only if

Insider Trading

Get notified when an Tg Therapeutics, Inc. insider buys or sells TGTX shares.

Notify only if

News

Receive news related to TG THERAPEUTICS, INC.

Track Activities on TGTX